PROK 1.51 (+3.42%)
KYG7S53R1049BiotechnologyBiotechnology

ProKidney (PROK) Stock Highlights

1.51 | +3.42%
2024-12-21 03:42:40
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patients own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patients own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.

Statistics

Range Today
1.41 1.54
Volume Today 1.34M
Range 1 Year
1.18 4.44
Volume 1 Year 174.89M
Range 3 Year
1.12 14.19
Volume 3 Year 319.86M
Range 10 Year
1.12 14.19
Volume 10 Year 333.15M

Highlights

Market Capitalization 1.81B (small)
Floating Shares 68.47M
Current Price 1.51
Price To Earnings -3.15
Earnings Per Share -0.62
Payout Ratio 0%

Performance

Latest +3.42%
1 Month -16.57%
3 Months -36.55%
6 Months -44.69%
1 Year -17.03%
3 Years -84.62%
5 Years -84.98%
10 Years -84.98%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.